11/20
07:33 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.
11/18
08:09 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/15
11:11 am
abus
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon [Yahoo! Finance]
Low
Report
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon [Yahoo! Finance]
11/15
11:11 am
abus
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B [Yahoo! Finance]
Medium
Report
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B [Yahoo! Finance]
11/15
11:02 am
abus
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Medium
Report
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
11/15
11:01 am
abus
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Medium
Report
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
11/14
07:30 am
abus
Arbutus to Present at Jefferies London Healthcare Conference
Low
Report
Arbutus to Present at Jefferies London Healthcare Conference
11/7
08:36 am
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/6
07:42 pm
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at Chardan Capital from $4.00 to $4.50. They now have a "buy" rating on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at Chardan Capital from $4.00 to $4.50. They now have a "buy" rating on the stock.
11/6
04:14 pm
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at JMP Securities to $5.00. They now have a "buy" rating on the stock.
Medium
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at JMP Securities to $5.00. They now have a "buy" rating on the stock.
11/6
10:15 am
abus
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/6
07:30 am
abus
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/23
07:30 am
abus
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Low
Report
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
10/15
08:25 am
abus
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024 [Financial Post (Toronto, Ontario, Canada)]
10/15
08:16 am
abus
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Medium
Report
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
10/1
07:30 am
abus
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Low
Report
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
9/25
11:43 am
abus
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]
9/5
07:08 pm
abus
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at Jefferies Financial Group Inc. from $5.00 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Arbutus Biopharma Co. (NASDAQ: ABUS) had its price target raised by analysts at Jefferies Financial Group Inc. from $5.00 to $7.00. They now have a "buy" rating on the stock.
9/3
07:41 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Arbutus to Participate in Two Upcoming Investor Conferences [Financial Post (Toronto, Ontario, Canada)]
9/3
07:30 am
abus
Arbutus to Participate in Two Upcoming Investor Conferences
Medium
Report
Arbutus to Participate in Two Upcoming Investor Conferences